Analysis of NAMCS data for multiple sclerosis, 1998–2004
Open Access
- 5 April 2007
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 5 (1) , 6
Abstract
To our knowledge, no study to date has investigated the prescribing patterns of immunomodulatory agents (IMAs) in an outpatient setting in the United States. To address this issue, we performed retrospective data analyses on National Ambulatory Medical Care Survey (NAMCS) data for MS patient visits between 1998 and 2004. NAMCS data are a weighted estimate of the nationwide frequency of patients' outpatient clinic visits. We analyzed NAMCS data in the following categories: (1) the proportion of MS patient visits to neurologists, family practitioners or internists, (2) age/gender/race/geographical distribution patterns in patient visits, and (3) the proportion of patients on IMA treatment among established MS patients. There were an estimated 6.7 million multiple sclerosis (MS) patient visits to the clinics between 1998–2004. Neurologists recorded the most patient visits, 50.7%. Patient visits were mostly in the fourth and fifth decade age group (57.9%). The male to female ratio was 1:4. No statistical evidence was observed for a decline or increase in IMA usage. About 62% patients visiting neurologists and 92% seen by family practitioners/internists were not using IMAs. Our results suggest that between the years 1998–2003, the use of interferon-1a tended to decline while the use of interferon-1b and glatiramer acetate, increased. Strategies that lead to improved use of IMAs in the management of MS in the outpatient setting are needed.Keywords
This publication has 26 references indexed in Scilit:
- Early Intervention in Multiple SclerosisDrugs, 2003
- The diagnosis of multiple sclerosisCurrent Opinion in Neurology, 2002
- Cost and health related quality of life consequences of multiple sclerosisMultiple Sclerosis Journal, 2000
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998
- A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complexNature Genetics, 1996
- A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22Nature Genetics, 1996
- EPIDEMIOLOGY OF MULTIPLE SCLEROSISNeurologic Clinics, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- How Many People in the World Have Multiple Sclerosis?Neuroepidemiology, 1994
- Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, CanadaNeurology, 1988